Heart failure therapies

new strategies for old treatments and new treatments for old strategies

Marc K Halushka, Richard N. Mitchell, Robert F. Padera

Research output: Contribution to journalReview article

Abstract

Heart failure, whether acute or chronic, remains a major health care crisis affecting almost 6 million Americans and over 23 million people worldwide. Roughly half of those affected will die within 5 years, and the annual cost exceeds $30 billion in the US alone. Although medical therapy has made some modest inroads in partially stemming the heart failure tsunami, there remains a significant population for whom medication is unsuccessful or has ceased being effective; such patients can benefit from heart transplantation or mechanical circulatory support. Indeed, in the past quarter century (and as covered in Cardiovascular Pathology over those years), significant improvements in pathologic understanding and in engineering design have materially enhanced the toolkit of options for such refractory patients. Mechanical devices, whether total artificial hearts or ventricular assist devices, have been reengineered to reduce complications and basic wear and tear. Transplant survival has also been extended through a better comprehension of and improved therapies for transplant vasculopathy and antibody-mediated rejection. Here we review the ideas and treatments from the last 25 years and highlight some of the new directions in nonpharmacologic heart failure therapy.

Original languageEnglish (US)
Pages (from-to)503-511
Number of pages9
JournalCardiovascular Pathology
Volume25
Issue number6
DOIs
StatePublished - Nov 1 2016

Fingerprint

Heart Failure
Heart-Assist Devices
Tsunamis
Transplants
Artificial Heart
Heart Transplantation
Therapeutics
Tears
Pathology
Delivery of Health Care
Costs and Cost Analysis
Equipment and Supplies
Antibodies
Population

Keywords

  • Antibody-mediated rejection
  • Cellular rejection
  • Heart failure
  • Orthotopic heart transplantation
  • Ventricular assist device

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Heart failure therapies : new strategies for old treatments and new treatments for old strategies. / Halushka, Marc K; Mitchell, Richard N.; Padera, Robert F.

In: Cardiovascular Pathology, Vol. 25, No. 6, 01.11.2016, p. 503-511.

Research output: Contribution to journalReview article

@article{386dcc55da9f426da8cf23687edf63e4,
title = "Heart failure therapies: new strategies for old treatments and new treatments for old strategies",
abstract = "Heart failure, whether acute or chronic, remains a major health care crisis affecting almost 6 million Americans and over 23 million people worldwide. Roughly half of those affected will die within 5 years, and the annual cost exceeds $30 billion in the US alone. Although medical therapy has made some modest inroads in partially stemming the heart failure tsunami, there remains a significant population for whom medication is unsuccessful or has ceased being effective; such patients can benefit from heart transplantation or mechanical circulatory support. Indeed, in the past quarter century (and as covered in Cardiovascular Pathology over those years), significant improvements in pathologic understanding and in engineering design have materially enhanced the toolkit of options for such refractory patients. Mechanical devices, whether total artificial hearts or ventricular assist devices, have been reengineered to reduce complications and basic wear and tear. Transplant survival has also been extended through a better comprehension of and improved therapies for transplant vasculopathy and antibody-mediated rejection. Here we review the ideas and treatments from the last 25 years and highlight some of the new directions in nonpharmacologic heart failure therapy.",
keywords = "Antibody-mediated rejection, Cellular rejection, Heart failure, Orthotopic heart transplantation, Ventricular assist device",
author = "Halushka, {Marc K} and Mitchell, {Richard N.} and Padera, {Robert F.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.carpath.2016.08.008",
language = "English (US)",
volume = "25",
pages = "503--511",
journal = "Cardiovascular Pathology",
issn = "1054-8807",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Heart failure therapies

T2 - new strategies for old treatments and new treatments for old strategies

AU - Halushka, Marc K

AU - Mitchell, Richard N.

AU - Padera, Robert F.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Heart failure, whether acute or chronic, remains a major health care crisis affecting almost 6 million Americans and over 23 million people worldwide. Roughly half of those affected will die within 5 years, and the annual cost exceeds $30 billion in the US alone. Although medical therapy has made some modest inroads in partially stemming the heart failure tsunami, there remains a significant population for whom medication is unsuccessful or has ceased being effective; such patients can benefit from heart transplantation or mechanical circulatory support. Indeed, in the past quarter century (and as covered in Cardiovascular Pathology over those years), significant improvements in pathologic understanding and in engineering design have materially enhanced the toolkit of options for such refractory patients. Mechanical devices, whether total artificial hearts or ventricular assist devices, have been reengineered to reduce complications and basic wear and tear. Transplant survival has also been extended through a better comprehension of and improved therapies for transplant vasculopathy and antibody-mediated rejection. Here we review the ideas and treatments from the last 25 years and highlight some of the new directions in nonpharmacologic heart failure therapy.

AB - Heart failure, whether acute or chronic, remains a major health care crisis affecting almost 6 million Americans and over 23 million people worldwide. Roughly half of those affected will die within 5 years, and the annual cost exceeds $30 billion in the US alone. Although medical therapy has made some modest inroads in partially stemming the heart failure tsunami, there remains a significant population for whom medication is unsuccessful or has ceased being effective; such patients can benefit from heart transplantation or mechanical circulatory support. Indeed, in the past quarter century (and as covered in Cardiovascular Pathology over those years), significant improvements in pathologic understanding and in engineering design have materially enhanced the toolkit of options for such refractory patients. Mechanical devices, whether total artificial hearts or ventricular assist devices, have been reengineered to reduce complications and basic wear and tear. Transplant survival has also been extended through a better comprehension of and improved therapies for transplant vasculopathy and antibody-mediated rejection. Here we review the ideas and treatments from the last 25 years and highlight some of the new directions in nonpharmacologic heart failure therapy.

KW - Antibody-mediated rejection

KW - Cellular rejection

KW - Heart failure

KW - Orthotopic heart transplantation

KW - Ventricular assist device

UR - http://www.scopus.com/inward/record.url?scp=84986612932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84986612932&partnerID=8YFLogxK

U2 - 10.1016/j.carpath.2016.08.008

DO - 10.1016/j.carpath.2016.08.008

M3 - Review article

VL - 25

SP - 503

EP - 511

JO - Cardiovascular Pathology

JF - Cardiovascular Pathology

SN - 1054-8807

IS - 6

ER -